INCB123667 + paclitaxel

**INCB123667 + paclitaxel** is an investigational combination therapy comprising INCB123667, a selective oral inhibitor of cyclin-dependent kinase 2 (CDK2), and paclitaxel, a standard microtubule-stabilizing chemotherapeutic agent. INCB123667 inhibits CDK2, thereby targeting cell cycle progression and proliferation in tumors, particularly those with cyclin E1 overexpression or CCNE1 amplification. Paclitaxel disrupts microtubule dynamics, leading to mitotic arrest and apoptosis. The combination is currently being studied in solid tumors, particularly in patients with advanced or metastatic gynecological malignancies such as platinum-resistant ovarian cancer, where cyclin E1 overexpression or CCNE1 amplification is common. The main objective is to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of the combination. The regimen is under clinical investigation and not currently approved for any indication[1][2][3][5][9].